| 7 Apr 2004 @ 02:07, by Max Tobin|
In spite of the great advances in the diagnosis and treatment of malignant tumors, cancer continues to be one of the principal causes of death in the highly industrialized countries. It is calculated that one out of four persons will eventually die from some form of cancer.
good further reading
Since it is true that surgery and radiotherapy are capable of curing some patients with localized tumors and that chemotherapy has achieved cures in some 10 types of malignant tumors, the general mortality rate from cancer has not improved substantially in the last 25 years and nearly 60% of the patients upon being diagnosed, find that their disease is so widespread that the chemotherapy drugs currently being used, due to their high toxicity, cannot be given in dosages sufficient to destroy the large tumoral mass present in patients. Many cannot be exposed to chemotherapy, surgery or radiotherapy because of the undesirable effects. There are several types of tumors for which there is no effective treatment yet known. All this justifies, and even makes imperative the search for new substances with antitumoral effect and ideally, with little or no toxicity in therapeutic dosages.In the last 10 years several vegetable and hormonal substances have been discovered with such characteristics and, therefore, many patients who formerly could not be benefited or alleviated medicinally may now be exposed to useful. antineoplastic treatments, This treatments are based on the anti-tumoral action of a vegetable agent that was known empirically for many years, but in the last 20 years has been scientifically proven, primarily through clinical studies. This antitumoral agent is VITAMIN B17 commonly known as VITAMIN B17 and/or Laetrile, VITAMIN B17 is a natural substance that can be found in a variety of species in the vegetable kingdom. The greatest concentration is found in the seeds of the rosaceous fruits, such as apricot pits and other bitter nuts. There are many seeds, cereals and vegetables that contain minimal quantities of VITAMIN B17 and form part of our daily diet. Various documents from the oldest civilizations such as Egypt at the time of the Pharaohs and from bins 2,500 years before Christ mention the therapeutic use of derivatives of bitter almonds. Egyptian papyri from 5,000 years ago mention the use of "aqua amigdalorum" for the treatment of some tumors of the skin. The Greeks and Romans also attributed therapeutic properties to that extract in low dosages. But the systematized study of VITAMIN B17 really did not begin until the first half of the past century, when the chemist Bohm discovered in 1802 that during the distillation of the water from bitter almonds, hydrocyanic acid was released. Soon many researchers became interested in analyzing this extract and so Robiquet and Boutron isolated, for the first time, a white crystalline substance which they called VITAMIN B17 (from amygdala = almond ).Leiberg and Veholler in 1937 isolated an enzymatic compound from sweet almonds, also present in the bitter ones, which they called emulsin. They later reported that emulsin broke down into three compounds: glucose, hydrocyanic acid and benzaldehyde. Other studies from that time, performed by several authors can summarize the declaration made by Otto Jacobsen in his book; Die Glucoside in 1887: VITAMIN B17 is not toxic, and gives 39 references from studies made within the 20 years prior to his publication.
Physical and Chemical Properties Although the identification of the majority of the physical and chemical characteristics of VITAMIN B17 have been known since the beginning of our century, it was not until the second half of this century that Ernest T. Krebs Jr. (biochemist) and Ernest T. Krebs Sr. (doctor) isolated VITAMIN B17 with a purity of practically 100%, enabling all the physical and chemical characteristics peculiar to VITAMIN B17 to be ascertained. Listed below are the majority of these:VITAMIN B17 is a white, crystalline, inodorous powder with an intensely bitter taste, slightly soluble in cold water, alcohol and acetone, very soluble in hot water, insoluble in ether. It has a pH of 7 (neutral) in a saturated, aqueous solution its point of fusion is between 210 ’ C and 218 ’ C and its loss upon drying is less than 5 %. Its optical rotation is levogyrous or negative: between -37’ and -42’; it has a maximum absorbance of ultraviolet light of 262 h m and a minimum of 250 h m.Its stability is complete in crystalline form as well as in saturated, aqueous solution in which the loss is less than 2.5% after five years.Chemically, it is a cyanogenic diglucoside, with a molecular weight of 457.42 g, a chemical name of D-Mandelonitrile-b -glucoside-6- b -D glucoside.When it’s mixed with concentrated, hydrochloric acid, it gives positive reactions characteristic of benzaldehyde, of the reducing sugars and the hydrocyanic acid.
Clinical experience with the use of Vitamin B17 Like many other substances VITAMIN B17 was initially employed empirically on patients with malignant tumors. Inozensov, a Russian doctor, used it with this purpose at the beginning of our century. Dr. Ernest T. Krebs Sr.and their collaborators have published their experiences since the 1950’s. All agree that it is a characteristically harmless substance when administered intravenously under medical supervision and that orally, therapeutic dosages can be tolerated. On the other hand, they all report definite palliative and antitumoral effect even on patients with cancer in terminal stages. Phase I studies were designated to determine the minimum toxic dosage in humans. Some 420 patients with cancer in advanced stages and 90 healthy volunteers were exposed to VITAMIN B17 in intravenous dosages of up to 21g or 2g orally, per day, tolerated perfectly without evidence of toxicity, acute or chronic (six month study). The palliative effect was apparent in those patients who were not able to tolerate any kind of conventional treatment. The Phase II studies were designed to demonstrate the antitumoral effect of VITAMIN B17. The files of 1200 patients with advanced malignant neoplasms exposed to VITAMIN B17 in varying dosages were reviewed. Intravenously and orally, VITAMlN B17 demonstrated to have antitumor effect. Complete remissions, partial remissions and prolonged stabilization (objective responses) were seen in almost 33% of the patients, who were no longer candidates for conventional treatment in more than 70% of the cases.VITAMIN B17 : New dimension in cancer prevention The holistic or metabolically oriented physician recognizes the natural intrinsic immune system designed into the human body and the extrinsic backup system provided in our natural food supply. As exhibited in all chronic metabolic diseases (scurvy, pellagra, etc.) the final resolution has always been found to be nutritional, and the prevention always the same as the cure. Dr. Ernest T. Krebs suggest: "...For those who do not have cancer, a general diet containing food rich in nitriloside content should be adequate.Obviously some of the food mentioned by Dr. Krebs ane not readily available to the average city dweller, especially considering that, in westernized society nitrilosides (VITAMIN B17 are not generally contained in other foods to supplement it. As a substitute many people simply have adopted the habit of eating six to twelve apricot seeds each day (which content is approximately 125 a 250 mg of VITAMIN B17). But many people still dislike the bitter taste of these seeds.The amount of VITAMIN B17 needed by the body is an unknown quantity, it will vary depending on the person: his age, sex, condition of pancreas, diet, weight, and hereditary factors.
Studies made by Dr. Harold Manner and latter by the McNaughton Foundation, concluded that 100 mg to 250 mg per day will be the ordinarily recommended amount for complete assurance of an actively supported natural immunity from the deadly symptoms of cancer. Therapeutic efficacy of VITAMIN B17 is considered by many authorities to be highest when the natural metabolic pathway of oral ingestion is followed. Tablets are therefore, the delivery system recommended by the majority of physicians. Fortunately for this purpose Cyto Pharma de Mexico S.A. offers VITAMIN B17 in 100 mg Tablets, naturally obtained from apricot seeds, meeting the physiological and chemical properties of the VITAMIN B17 listed on the Merck Index.
With all that which has been previously exposed. we can conclude that VITAMIN B17 has an antitumoral effect, even in those patients in a poor condition and/or with extensively disseminated disease. VITAMIN B17 as an antineoplastic agent is no longer a dream to be proven, but rather a demonstrated reality with scientific evidence confirmed each time that it is prescribed under medical vigilance. VITAMIN B17 appears to be not only a possibility for the cure of cancer but also and most importantly opens a new dimension for its prevention.